FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells — aged, dysfunctional "zombie cells" that accumulate in tissues and drive chronic inflammation, tissue dysfunction, and age-related disease. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing them to undergo apoptosis while leaving healthy cells unaffected. It is one of the first peptide-based senolytics and has generated significant interest in the longevity research community.
Category: Senolytic / Anti-Aging. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical. No human clinical trials. Animal studies in aged mice (Baar et al., Cell 2017).
Senescent cells survive because FOXO4 protein binds to p53 in the nucleus, sequestering it and preventing p53 from triggering apoptosis. FOXO4-DRI is a modified peptide that competes with endogenous FOXO4 for p53 binding but cannot sequester p53 effectively. This causes p53 nuclear exclusion,…
Research base: 0 registered clinical trials and 7 indexed publications reference FOXO4-DRI.
Safety considerations: No human safety data exists; Mouse studies used doses of 5 mg/kg via intraperitoneal injection; Transient weight loss and reduced food intake observed in treated mice.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
Senescent cells are cells that have permanently stopped dividing but resist apoptosis (programmed death). They accumulate with age and secrete inflammatory molecules (SASP — senescence-associated secretory phenotype) that damage surrounding tissue, drive chronic inflammation, and contribute to age-related diseases including cancer, cardiovascular disease, and neurodegeneration.
There are no human safety studies. All data comes from mouse models. The peptide is a research compound only. Self-experimentation carries unknown risks including potential disruption of beneficial senescent cell functions in wound healing and tumor suppression.
Other senolytics include dasatinib+quercetin (D+Q) and fisetin, which are small molecules with human pilot data. FOXO4-DRI is the only peptide-based senolytic with published data. Its mechanism (FOXO4-p53 disruption) is more selective than D+Q but less studied in humans.